Page 8 - Sosei Group News Today

Share this article Share this article TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December...

 Global Autism Therapy Market   Global Autism Therapy Market research report has been prepared with a nice combination of industry insight, smart solutions, practical solutions and newest technology to give better user experience. Under market segmentation chapter, research and analysis is done based on several market and industry segments such as application, vertical, deployment model, end user, and geography. To perform this market research study, competent and advanced tools and techniqu...

Sosei Heptares Operational Highlights and Consolidated Results for the First Quarter 2021 News provided by Share this article Share this article TOKYO and CAMBRIDGE, England, May 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2021. The full report can be accessed by clicking here.  Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, c...

Share this article Share this article TOKYO and CAMBRIDGE, England, March 11, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has dosed the first patient in a 370-patient randomized Phase 3 clinical trial of APP13007 in the United States (ClinicalTrials.gov Identifier: NCT04739709). APP13007 is a nanoparticle formulation of a steroid in development for the treatment of inflammation and pain after cataract surgery...

Sosei Heptares Operational Highlights and Consolidated Results for the 12 Months ended 31 December 2020 News provided by Share this article Share this article TOKYO and CAMBRIDGE, England, Feb. 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2020. The full report can be accessed by clicking here.  Shinichi Tamura, Chairman, President and CEO of Sose...

Share this article Share this article TOKYO and CAMBRIDGE, England, Feb. 1, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company"; TSE: 4565) announces it will apply its world-leading structure-based drug design (SBDD) expertise and platform to ion channels for the first time through a new strategic collaboration with Metrion Biosciences Limited ("Metrion"), the specialist ion channel CRO and drug discovery company. Ion channels are a class of integral membrane proteins that regulate the...

Share this article Share this article TOKYO and CAMBRIDGE, England, Jan. 12, 2021 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) and PharmEnable, a UK drug discovery company, announce they have entered a collaboration to apply their respective technologies to drive novel drug discovery against a challenging G protein-couple receptor (GPCR) target associated with neurological diseases. The collaboration will combine Sosei Heptares world-leading GPCR-focused structure-bas...

Sosei Heptares and Captor Therapeutics Enter Strategic Technology Collaboration Focused on Targeted GPCR Degradation as Novel Approach for Drug Design - Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders - Unique combination of novel technologies to enhance GPCR drug discovery and expand capabilities into wider drug target universe News provided by Share this article Share this article TOKYO and CAMBRI...

Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System - Single-target agreement focused on small molecule agonists of GPR35, a genetically validated target for inflammatory bowel disease and other gastrointestinal immune disorders - Sosei Heptares eligible to receive an upfront payment, research funding and potential near-term development milestones of up to £34 million (US$44 million), potential downstream payments of up to ...